

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

Two new flavan-4-ol glycosides from *Abacopteris penangiana*

Jin-Bo Fang^{ab}, Jia-Chun Chen^b, Hong-Quan Duan^c

^a School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China ^b Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, Tongji Pharmaceutical College, Huazhong University of Science and Technology, Wuhan, China ^c School of Pharmaceutical Sciences, Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin, China

Online publication date: 20 May 2010

To cite this Article Fang, Jin-Bo, Chen, Jia-Chun and Duan, Hong-Quan(2010) 'Two new flavan-4-ol glycosides from *Abacopteris penangiana*', Journal of Asian Natural Products Research, 12: 5, 355 – 359

To link to this Article: DOI: 10.1080/10286021003764453

URL: <http://dx.doi.org/10.1080/10286021003764453>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

ORIGINAL ARTICLE

Two new flavan-4-ol glycosides from *Abacopteris penangiana*

Jin-Bo Fang^{ab}, Jia-Chun Chen^b and Hong-Quan Duan^{c*}

^aSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China;

^bHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, Tongji Pharmaceutical College, Huazhong University of Science and Technology, Wuhan 430030, China;

^cSchool of Pharmaceutical Sciences, Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China

(Received 8 December 2009; final version received 8 March 2010)

Two new flavan-4-ol glycosides, (2*R*,4*S*)-6,8-dimethyl-7-hydroxy-4'-methoxy-4,2''-oxidoflavan-5-*O*- β -D-6''-*O*-acetyl-glucopyranoside (**1**) and (2*R*,4*S*)-5,7-*O*- β -D-di-glucopyranosyloxy-4'-methoxy-6,8-dimethyl-4,2''-oxidoflavane (**2**), were isolated from the rhizomes of *Abacopteris penangiana*. Their structures were elucidated by spectroscopic methods. Compounds **1** and **2** showed significant anticancer activities against HeLa and L929 cell lines *in vitro*.

Keywords: Amaranthaceae; *Abacopteris penangiana*; flavan-4-ol glycoside; antitumor activity

1. Introduction

Abacopteris penangiana (Hook.) Ching is a fern growing at an altitude of 1900–3600 m in the south of China. As a folk medicine, it has been used to treat infections in the pharynx and larynx [1]. Several infrequent flavan-4-ol glycosides have been isolated from submarginal ferns [2–5].

This paper deals with the isolation and structural elucidation of two new flavan-4-ol glycosides, named (2*R*,4*S*)-6,8-dimethyl-7-hydroxy-4'-methoxy-4,2''-oxidoflavan-5-*O*- β -D-6''-*O*-acetyl-glucopyranoside (**1**) and (2*R*,4*S*)-5,7-*O*- β -D-di-glucopyranosyloxy-4'-methoxy-6,8-dimethyl-4,2''-oxidoflavane (**2**) (Figure 1), as well as their cytotoxic activities. Their structures were established by spectroscopic methods, especially by a series of 2D NMR


experiments (¹H–¹H COSY, NOESY, HSQC, and HMBC) and HRMS.

2. Results and discussion

Compound **1** was obtained as an amorphous white powder. Its HR-ESI-MS showed an [M + Na]⁺ ion at *m/z* 525.1721, corresponding to the molecular formula C₂₆H₃₀O₁₀. Its UV spectrum showed the absorption maxima at 281 (log ϵ 4.01), 274 (log ϵ 4.03), 222 (log ϵ 4.75), and 207 (log ϵ 4.97) nm, and the IR spectrum showed the presence of a hydroxyl group (3452 cm⁻¹), carbonyl (1660 cm⁻¹), and aromatic rings (1616 and 1516 cm⁻¹).

The ¹H NMR spectrum (Table 1) of **1** revealed the presence of two methyls at δ_{H} 2.05 and 2.08 (each 3H, s), an acetyl methyl group (δ_{H} 2.06, 3H, s), one methoxyl (δ_{H} 3.81, 3H, s), an AA'XX'

*Corresponding author. Email: duanhq@tjmu.edu.cn



- 1 $R_1 = H$ $R_2 = CH_3CO$
 2 $R_1 = \beta\text{-D-Glu}$ $R_2 = H$

Figure 1. The structures of compounds **1** and **2**.

coupling system proton at δ_H 7.43 (2H, dd, $J = 2.0, 8.7$ Hz, H-2', 6') and 6.93 (2H, dd, $J = 2.0, 8.7$ Hz, H-3', 5'), two oxygenated methine protons at δ_H 4.86 (1H, br d, $J = 11.6$ Hz) and 5.09 (1H, dd, $J = 1.7, 4.7$ Hz), one methylene at δ_H 1.95 (1H, ddd, $J = 3.0, 11.6, 16.5$ Hz), 2.30 (1H, dd, $J = 2.0, 16.5$ Hz), and an anomeric proton signal at δ_H 5.11 (1H, d, $J = 8.4$ Hz).

Its ^{13}C NMR spectrum showed 26 carbons, including one acetyl, two benzene rings, one glucose, one methoxy, two oxygenated methines, one methylene, and two methyl carbon signals. From the above observations, compound **1** was deduced to be a flavan-4-ol glycoside, and its ^{13}C NMR spectral data were similar to those of 5,7-dihydroxy-4'-methoxy-6,8-dimethyl-2'',4(S)-oxido-2(R)-flavan-5- β -D-glucopyranoside (eruberin A) [6], except for an additional acetyl group.

From the ^1H - ^1H COSY spectrum, a substructure, $-\text{O}-\text{CH}-\text{CH}_2-\text{CH}-\text{O}-$, was concluded from the correlations of H₂-3 (δ_H 1.95, 2.30) with H-2 (δ_H 4.86) and H-4 (δ_H 5.09). The coupling constants of H-2 (δ_H 4.86, br d, $J = 11.6$ Hz), H-3_{ax} (δ_H 1.95, ddd, $J = 3.0, 11.6, 16.5$ Hz), H-3_{eq} (δ_H 2.30, dd, $J = 2.0, 16.5$ Hz), H-4 (δ_H 5.09, dd, $J = 1.7, 4.7$ Hz), and the values of $[\alpha]_D$ were consistent with those

of eruberin A [6], which suggested that the configurations at C-2 and C-4 were 2*R* and 4*S*.

In the HMBC spectrum, the anomeric proton H-1'' (δ_H 5.11, glucose) correlated with the signal at δ_C 151.2 (C-5), H-2'' (δ 3.61) with C-4 at δ_C 67.2, and H-4 at δ_H 5.09 with C-2'' at δ_C 76.5. The above observations indicated that the anomeric carbon (C-1'') was connected to C-5 and C-2'' to C-4 through O-linkages. On the other hand, the signal at δ_H 3.81 (4'-OMe) showed correlations with the signal at δ_C 160.9 (C-4'). The signals at δ_H 4.45, 4.19 (H₂-6'') were correlated with the acetyl carbonyl carbon at δ_C 172.8, which indicated that the acetyl group was assigned at position C-6'' (Figure 2). Therefore, the structure of compound **1** was deduced to be (2*R*,4*S*)-6,8-dimethyl-7-hydroxy-4'-methoxy-4,2''-oxidoflavan-5-*O*- β -D-6''-*O*-acetyl-glucopyranoside (Figure 1).

Compound **2**, an amorphous white powder, had the molecular formula $\text{C}_{30}\text{H}_{38}\text{O}_{14}$ from HR-ESI-MS. The ^1H and ^{13}C NMR spectral data (Table 1) were similar to those of compound **1**, except for the presence of an additional glucose and the absence of an acetyl group at C-6''. The HMBC correlation between the anomeric proton (δ_H 4.65, Glu H-1''') and C-7 at δ_C 156.2 indicated that another glucose moiety was located at C-7 of the flavan-4-ol. The ^1H and ^{13}C NMR signal assignments were achieved by the combination of ^1H - ^1H COSY, HSQC, and HMBC spectral elucidation. Thus, the structure of compound **2** was elucidated to be (2*R*,4*S*)-5,7-*O*- β -D-di-glucopyranosyloxy-4'-methoxy-6,8-dimethyl-4,2''-oxidoflavane.

The antineoplastic activity of compounds **1** and **2** was determined by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay with two tumor cell lines: human neuroblastoma cell line (HeLa) and human leukemia cell line (L929). Compounds **1** and **2** showed significant

Table 1. ¹H NMR (300 MHz) and ¹³C NMR (75 MHz) spectral data of **1** and **2** (CD₃OD, TMS, δ in ppm).

Position	1		2	
	δ _H	δ _C	δ _H	δ _C
2	4.86 (1H, br d, 11.6 Hz)	74.8 (d)	4.86 (1H, br d, <i>J</i> = 11.6 Hz)	74.9 (d)
3	1.95 (1H, ddd, <i>J</i> = 3.0, 11.6, 16.5 Hz, H-3 _{ax}), 2.30 (1H, dd, <i>J</i> = 2.0, 16.5 Hz, H-3 _{eq})	38.5 (t)	1.95 (1H, ddd, <i>J</i> = 3.0, 11.6, 16.5 Hz, H-3 _{ax}), 2.32 (1H, dd, <i>J</i> = 2.0, 16.5 Hz, H-3 _{eq})	38.2 (t)
4	5.09 (1H, dd, <i>J</i> = 1.7, 4.7 Hz)	67.2 (d)	5.11 (1H, dd, <i>J</i> = 1.7, 4.7 Hz)	67.0 (d)
5		151.2 (s)		151.6 (s)
6		111.1 (s)		117.2 (s)
6-Me	2.05 (3H, s)	9.4 (s)	2.08 (3H, s)	10.8 (s)
7		156.2 (s)		156.2 (s)
8		109.6 (s)		118.1 (s)
8-Me	2.08 (3H, s)	8.7 (q)	2.29 (3H, s)	10.4 (q)
9		152.9 (s)		152.9 (s)
10		105.4 (s)		109.7 (s)
1'		134.9 (s)		134.6 (s)
2'/6'	7.43 (2H, dd, <i>J</i> = 2.0, 8.7 Hz)	128.7 (d)	7.42 (2H, dd, <i>J</i> = 2.0, 8.7 Hz)	128.7 (d)
3'/5'	6.93 (2H, dd, <i>J</i> = 2.0, 8.7 Hz)	114.9 (d)	6.94 (2H, dd, <i>J</i> = 2.0, 8.7 Hz)	114.9 (d)
4'		160.9 (s)		161.0 (s)
4'-OMe	3.81 (3H, s)	55.8 (q)	3.81 (3H, s)	55.8 (q)
5-Glu				
1''	5.11 (1H, d, <i>J</i> = 8.4 Hz)	102.4 (d)	5.17 (1H, d, <i>J</i> = 8.0 Hz)	102.7 (d)
2''	3.61 (1H, m)	76.5 (d)	3.41 (1H, m)	79.1 (d)
3''	3.29 (1H, m)	75.8 (d)	3.32 (1H, m)	76.1 (d)
4''	3.19 (1H, m)	71.7 (d)	3.37 (1H, m)	71.8 (d)
5''	3.54 (1H, ddd, <i>J</i> = 2.0, 2.2, 3.7 Hz)	76.1 (d)	3.60 (1H, m)	76.7 (d)
6''	4.45 (1H, dd, <i>J</i> = 2.1, 11.8 Hz), 4.19 (1H, dd, <i>J</i> = 5.9, 11.8 Hz)	64.6 (t)	3.63 (1H, dd, <i>J</i> = 1.5, 6.0 Hz), 3.67 (1H, dd, <i>J</i> = 1.5, 6.0 Hz)	63.0 (t)
6''-OCOCH ₃	2.06 (3H, s)	172.8 (s), 20.8 (q)		
7-Glu				
1'''			4.65 (1H, d, <i>J</i> = 7.5 Hz)	105.6 (d)
2'''			3.41 (1H, m)	78.0 (d)
3'''			3.17 (1H, m)	75.8 (d)
4'''			3.52 (1H, m)	71.7 (d)
5'''			3.42 (1H, m)	78.0 (d)
6'''			3.77 (1H, dd, <i>J</i> = 2.2, 11.9 Hz), 3.90 (1H, dd, <i>J</i> = 2.2, 11.9 Hz)	62.9 (t)




Figure 2. Key HMBC correlations of compound **1**.

inhibitory effect against HeLa (IC_{50} 22.52, 37.68 $\mu\text{g/ml}$) and L929 (IC_{50} 36.75, 64.39 $\mu\text{g/ml}$) cell lines, respectively.

3. Experimental

3.1 General experimental procedures

IR spectra were recorded as KBr pellets by a NICOLET 380 spectrometer (Thermo Electron Corporation, Waltham, MA, USA). UV spectra were obtained on a UVIKON_{XS} recording spectrometer (BIO-TEK, Winooski, VT, USA). Optical rotation was measured with an MC 241 digital polarimeter (Perkin-Elmer, Waltham, MA, USA). The NMR samples were run on a Bruker AVANCE 300 instrument (^1H NMR, 300 MHz; ^{13}C NMR, 75 MHz) using tetramethylsilane as the internal standard for both ^1H and ^{13}C NMR analyses. MS data were obtained on an IonSpec 4.7-Tesla Fourier-transform mass spectrometer. Silica gel (300–400 mesh; Qingdao Marine Chemical Co. Ltd, Qingdao, China) was used for column chromatography. TLC plates were performed on silica gel F₂₅₄. All compounds were detected by spraying with Ce_2SO_4 , followed by heating. Flash chromatography was carried out on a column (C18 HS 40M 1621-1; Biotage, Inc., Suite C Charlotte, NC, USA). HPLC separation was performed on a JASCO Gulliver Series with

PU-2089 (pump), and RI-2031 and UV-2075 (detectors). The GPC column (gel permeation chromatography, Jordi, K-806M, 10.8 mm \times 500 mm \times 2) was used as the preparative HPLC with a mobile phase CHCl_3 .

3.2 Plant material

The rhizomes of *A. penangiana* (Hook.) Ching were collected in Jianshi County, Hubei Province of China in November 2004 and identified by Prof. Ding-Rong Wan (School of Life Sciences, South-Central University for Nationalities). A voucher specimen (D20050103) has been deposited at the School of Pharmaceutical Sciences, Tianjin Medical University, China.

3.3 Extraction and isolation

The dried aerial parts (5.4 kg) of *A. penangiana* were crushed and extracted three times with EtOH (95%, 20 liters each) under reflux for 6 h. The EtOH extract was concentrated *in vacuo* to give a residue (750 g), which was suspended in H_2O , and then partitioned with petroleum ether (PE), EtOAc, and *n*-BuOH, successively. The PE extract (32.5 g) was chromatographed on a silica gel (100–200 mesh) column eluting with solvents of increasing polarity [650 g silica gel; PE–EtOAc (8:1, 5:1, 3:1, 1:1, 1:2, 1:4), EtOAc, EtOAc–MeOH (19:1, 9:1, 4:1), MeOH] to yield 17 fractions (1–17). Fraction 12 (1.6 g) was chromatographed on a silica gel flash column (CHCl_3 –MeOH) and further purified by HPLC (GPC, CHCl_3) to yield compounds **1** (12.2 mg) and **2** (7.2 mg).

3.3.1 (2*R*,4*S*)-6,8-Dimethyl-7-hydroxy-4'-methoxy-4,2''-oxidoflavan-5-*O*- β -*D*-6''-*O*-acetyl-glucopyranoside (**1**)

An amorphous white powder; $[\alpha]_{\text{D}}^{25} + 81$ ($c = 1.00$, MeOH); IR (KBr) ν_{max} : 3452, 2891, 1724, 1616, 1516, 1471, 1373, 1339, 1248, 1143, 1068, 942, 835 cm^{-1} ; UV

(MeOH) λ_{\max} ($\log \epsilon$): 206 (4.63), 227 (4.39), 274 (3.87), 280 (3.89) nm; ^1H and ^{13}C NMR spectral data see Table 1; positive HR-ESI-TOF-MS m/z : 525.1721 $[\text{M} + \text{Na}]^+$ (calcd for $\text{C}_{26}\text{H}_{30}\text{O}_{10}\text{Na}$, 525.1737).

3.3.2 (2R,4S)-5,7-O- β -D-Di-glucopyranosyloxy-4'-methoxy-6,8-dimethyl-4,2''-oxidoflavane

An amorphous white powder; $[\alpha]_{\text{D}}^{25} + 63$ ($c = 0.45$, MeOH); IR (KBr) ν_{\max} : 3417, 2889, 1613, 1515, 1461, 1343, 1250, 1069, 947, 894, 832 cm^{-1} ; UV (MeOH) λ_{\max} ($\log \epsilon$): 206 (4.63), 224 (4.40), 281(3.89) nm; ^1H and ^{13}C NMR spectral data see Table 1; positive HR-ESI-TOF-MS m/z : 645.2169 $[\text{M} + \text{Na}]^+$ (calcd for $\text{C}_{30}\text{H}_{38}\text{O}_{14}\text{Na}$, 645.2159).

3.4 Cytotoxicity assay

Procedure of the bioassay was reported in the previous paper [7].

Acknowledgement

This work was sponsored by the Scientific Research Foundation of Tianjin Medical University.

References

- [1] Jiangsu New Medical College, *Dictionary of Chinese Traditional Medicine* (Shanghai Scientific and Technologic Press, Shanghai, 1977), p. 1633.
- [2] N. Tanaka, T. Ushioda, H. Fuchino, and J.E. Braggins, *Aust. J. Chem.* **50**, 329 (1997).
- [3] Z.X. Zhao, J.L. Ruan, J. Jin, J. Zou, D.N. Zhou, W. Fang, and F.B. Zeng, *J. Nat. Prod.* **69**, 265 (2006).
- [4] Z.X. Zhao, J. Jin, J.L. Ruan, C.C. Zhu, C.Z. Lin, W. Fang, and Y.L. Cai, *J. Nat. Prod.* **70**, 1683 (2007).
- [5] Z.X. Zhao, J. Jin, J.L. Ruan, Y.L. Cai, and C.C. Zhu, *Acta Pharm. Sin.* **43**, 392 (2008).
- [6] N. Tanaka, T. Sada, T. Murakami, Y. Saiki, and C.M. Chen, *Chem. Pharm. Bull.* **32**, 490 (1984).
- [7] J.T. Zhang, *Modern Pharmacological Experiment Methods* (Peking Union Medical College Press, Peking, 1998), p. 701.